Intercept ICPT reported positive top-line results from its phase 3 results of obeticholic acid (OCA) in patients with liver fibrosis due to nonalcoholic steatohepatitis (NASH) on Feb. 19. The trial ...

The market expects Intercept Pharmaceuticals (ICPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2021. This widely-known ...

Intercept Pharmaceuticals, Inc. ICPT announced initial results from a planned interim analysis of its ongoing phase II study 747-213. The comparative study is evaluating the therapeutic potential of ...

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients Trial met the primary efficacy ...

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver disease drug Ocaliva is under serious threat. Looking to assess whether Ocaliva ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Intercept Pharmaceuticals (ICPT) reports results for the quarter ended December 2022. While this widely-known consensus ...

The market expects Intercept Pharmaceuticals (ICPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2021. This widely-known ...

The market expects Intercept Pharmaceuticals (ICPT) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2021. This widely-known ...